How to manage primary amyloidosis (Q46400142)

21 December 2017

title

How to manage primary amyloidosis (English)

1 reference

21 December 2017

author name string

M A Gertz

series ordinal

1

1 reference

21 December 2017

publication date

26 August 2011

1 reference

21 December 2017

published in

Leukemia

1 reference

21 December 2017

volume

26

1 reference

21 December 2017

issue

2

1 reference

21 December 2017

page(s)

191-198

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2011.219

exact match

0 references

cites work

Light chain amyloidosis - current findings and future prospects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Structural Alterations within Native Amyloidogenic Immunoglobulin Light Chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Urine cytology of localized primary amyloidosis of the ureter: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

An uncommon cause of bilateral pulmonary nodules in a long-term smoker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Primary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Localized AL amyloidosis of the colon: an unrecognized entity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Localized amyloidosis of the stomach: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Mineral metabolism disturbances in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Selective silencing of a mutant transthyretin allele by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Liver transplantation for inherited metabolic disorders of the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Cardiac amyloidosis: an approach to diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Systemic amyloidosis: a challenge for the rheumatologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Amyloidosis: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Prognostic significance of strain Doppler imaging in light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Serum uric acid: novel prognostic factor in primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Treatment of "primary" renal amyloidosis with melphalan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

Primary cutaneous localized amyloid elastosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Localized amyloidosis of the urinary bladder, clinically masquerading as bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Localized amyloidosis of the urinary tract: case series of nine patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Complete resolution of laryngeal amyloidosis with radiation treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Primary tracheobronchial amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Laser therapy in patient with intractable haemorrhage due to the bladder involvement of systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Spotlight focuses on protein-misfolding therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Noninvasive diagnosis of cardiac amyloidosis by MRI and echochardiography

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

High-Dose Chemotherapy with Autotransplantation in AL Amyloidosis: A Flawed Meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

I don't know how to treat amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.219

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.219

1 reference

21 December 2017

PubMed ID

21869840

1 reference

21 December 2017